Get the Stockscreener App
30.12
8.89%
2.46
After Hours:
29.54
-0.58
-1.93%
Rapport Therapeutics Inc stock is traded at $30.12, with a volume of 599.45K.
It is up +8.89% in the last 24 hours and up +2.10% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$27.66
Open:
$27.475
24h Volume:
599.45K
Relative Volume:
1.54
Market Cap:
$1.44B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.73%
1M Performance:
+2.10%
6M Performance:
+150.17%
1Y Performance:
+69.36%
1-Day Range:
$27.48
$30.79
1-Week Range:
$26.60
$30.79
52-Week Range:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
30.12 | 1.32B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
Have Rapport Therapeutics Insiders Been Selling Stock? - simplywall.st
Form 424B5 Rapport Therapeutics, - StreetInsider
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program - TradingView — Track All Markets
Rapport Therapeutics Advances RAP-219 into Phase 3 Trials for Focal Onset Seizures, Expands Epilepsy Portfolio with New Program - Quiver Quantitative
Rapport Therapeutics Announces Accelerated Initiation of - GlobeNewswire
What technical charts say about Rapport Therapeutics Inc. stock2026 world cup usa national team qualification goalkeepers possession football odds analysis preview - ulpravda.ru
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 2,840 Shares - Defense World
Behavioral Patterns of RAPP and Institutional Flows - Stock Traders Daily
Krishnaswamy Yeleswaram Sells 2,840 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $197,338.35 in Stock - MarketBeat
Is Rapport Therapeutics Inc a good long term investmentSupport Level Holds & Free Discover Fast Growing Stocks - earlytimes.in
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.2%Here's What Happened - MarketBeat
Guidance Update: Will Rapport Therapeutics Inc stock continue dividend increasesBull Run & AI Optimized Trade Strategies - moha.gov.vn
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Liquidity Mapping Around (RAPP) Price Events - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? - AOL.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
How sustainable is Rapport Therapeutics Inc. stock dividend payoutWeekly Trade Review & Proven Capital Preservation Tips - Улправда
Can Rapport Therapeutics Inc. stock resist market sell offsMarket Activity Report & Growth Focused Stock Pick Reports - DonanımHaber
Rapport Therapeutics stock holds Buy rating at Goldman Sachs on epilepsy drug efficacy - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $172,890.12 in Stock - MarketBeat
Rapport Therapeutics CEO Sells Shares Worth Over $323K - TradingView — Track All Markets
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Will Rapport Therapeutics Inc. stock outperform growth indexesJuly 2025 Selloffs & Daily Profit Maximizing Tips - Улправда
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $255,170.00 in Stock - MarketBeat
Rapport Therapeutics CSO Sells Shares Under Trading Plan - TradingView — Track All Markets
Rapport Therapeutics Earnings Notes - Trefis
Assessing Rapport Therapeutics (RAPP) Valuation After Positive RAP-219 Phase 2a Epilepsy Data and Phase 3 Plans - Sahm
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to Hold - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 5.4%Here's Why - MarketBeat
Rapport Therapeutics Shapes Focused Clinical Neuroscience Programs - Kalkine Media
HC Wainwright Issues Optimistic Forecast for RAPP Earnings - Defense World
FY2027 Earnings Forecast for RAPP Issued By HC Wainwright - MarketBeat
Rapport Therapeutics price target raised to $40 from $34 at HC Wainwright - MSN
Rapport Therapeutics, Inc. (RAPP) is up 9.03% in one week: What you should know - MSN
HC Wainwright & Co. Maintains Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) Receives “Buy” Rating from BTIG Research - Defense World
Certain Stock Options of Rapport Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Common Stock of Rapport Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Earns Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics announces new data, post hox analysis on RAP-219 - MSN
Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge - Yahoo Finance
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yeleswaram Krishnaswamy | Chief Development Officer |
Dec 31 '25 |
Sale |
30.05 |
2,840 |
85,342 |
296,991 |
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):